IT9068053A0 - Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi e terapia di affezioni tumorali e suo impiego - Google Patents
Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi e terapia di affezioni tumorali e suo impiegoInfo
- Publication number
- IT9068053A0 IT9068053A0 IT9068053A IT6805390A IT9068053A0 IT 9068053 A0 IT9068053 A0 IT 9068053A0 IT 9068053 A IT9068053 A IT 9068053A IT 6805390 A IT6805390 A IT 6805390A IT 9068053 A0 IT9068053 A0 IT 9068053A0
- Authority
- IT
- Italy
- Prior art keywords
- avidin
- biotin
- diagnosis
- therapy
- monoclonal antibodies
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title 2
- 108090001008 Avidin Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229960002685 biotin Drugs 0.000 title 1
- 235000020958 biotin Nutrition 0.000 title 1
- 239000011616 biotin Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT06805390A IT1245748B (it) | 1990-12-21 | 1990-12-21 | Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego |
| EP91121419A EP0496074B1 (en) | 1990-12-21 | 1991-12-13 | Biotinylated monoclonal antibodies, avidin and biotin for diagnosis and therapy |
| DE69123235T DE69123235T2 (de) | 1990-12-21 | 1991-12-13 | Biotinylierte monoklonale Antikörper, Avidin und Biotin für die Diagnose und Therapie |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT06805390A IT1245748B (it) | 1990-12-21 | 1990-12-21 | Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IT9068053A0 true IT9068053A0 (it) | 1990-12-21 |
| IT9068053A1 IT9068053A1 (it) | 1992-06-22 |
| IT1245748B IT1245748B (it) | 1994-10-14 |
Family
ID=11307501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT06805390A IT1245748B (it) | 1990-12-21 | 1990-12-21 | Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0496074B1 (it) |
| DE (1) | DE69123235T2 (it) |
| IT (1) | IT1245748B (it) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6416738B1 (en) | 1973-12-07 | 2002-07-09 | Neorx Corporation | Pretargeting methods and compounds |
| US6075010A (en) * | 1992-06-09 | 2000-06-13 | Neorx Corporation | Small molecular weight ligand-hexose containing clearing agents |
| US5525338A (en) * | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
| US5911969A (en) | 1992-06-09 | 1999-06-15 | Neorx Corporation | Pretargeting protocols for enhanced localization of active agents to target sites |
| US5624896A (en) * | 1992-06-09 | 1997-04-29 | Neorx Corporation | Clearing agents useful in pretargeting methods |
| US5616690A (en) * | 1992-06-09 | 1997-04-01 | Neorx Corporation | Hexose derivatized human serum albumin clearing agents |
| US5578287A (en) * | 1992-06-09 | 1996-11-26 | Neorx Corporation | Three-step pretargeting methods using improved biotin-active agent |
| US5541287A (en) * | 1992-06-09 | 1996-07-30 | Neorx Corporation | Pretargeting methods and compounds |
| US5914312A (en) * | 1992-06-09 | 1999-06-22 | Neorx Corporation | Pretargeting methods and compounds |
| US6217869B1 (en) | 1992-06-09 | 2001-04-17 | Neorx Corporation | Pretargeting methods and compounds |
| CA2134239C (en) * | 1992-06-09 | 2004-11-23 | Donald B. Axworthy | Pretargeting methods and compounds |
| US6358490B2 (en) | 1992-06-09 | 2002-03-19 | Neorx Corporation | Three-step pretargeting methods and compounds |
| US6022966A (en) * | 1993-11-22 | 2000-02-08 | Neorx Corporation | Pretargeting methods and compounds |
| US5976535A (en) * | 1992-06-09 | 1999-11-02 | Neorx Corporation | Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore |
| GB9300686D0 (en) * | 1993-01-15 | 1993-03-03 | Imp Cancer Res Tech | Compounds for targeting |
| GB2300859B (en) * | 1993-01-15 | 1997-06-18 | Imp Cancer Res Tech | Compounds comprising a target cell-specific portion and a further portion |
| IL108388A0 (en) * | 1993-01-21 | 1994-04-12 | Harvard College | Amplified direction of effector groups to specific target cells in an animal |
| US5482698A (en) * | 1993-04-22 | 1996-01-09 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin polymer conjugates |
| IL109666A0 (en) * | 1993-05-17 | 1994-08-26 | Immunomedics Inc | A targeting composition containing a biotin- or avidinprotein conjugate and methods for the use thereof |
| US6120768A (en) * | 1993-05-17 | 2000-09-19 | Immunomedics, Inc. | Dota-biotin derivatives |
| CA2178476A1 (en) * | 1993-12-07 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
| US6015897A (en) * | 1993-12-07 | 2000-01-18 | Neorx Corporation | Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota |
| WO1995015978A1 (en) * | 1993-12-07 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
| WO1995015770A1 (en) * | 1993-12-09 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
| IL112372A (en) * | 1994-02-07 | 2001-08-26 | Res Dev Foundation | Non-viral vector for the delivery of genetic information to cells |
| US6172045B1 (en) | 1994-12-07 | 2001-01-09 | Neorx Corporation | Cluster clearing agents |
| US6908903B1 (en) | 1994-12-07 | 2005-06-21 | Aletheon Pharmaceuticals, Inc. | Cluster clearing agents |
| US5955605A (en) * | 1995-02-21 | 1999-09-21 | Neorx Corporation | Biotinidase resistant biotin-DOTA conjugates |
| EP0840797B1 (en) | 1995-07-25 | 2014-09-03 | Crucell Holland B.V. | Methods and means for targeted gene delivery |
| ES2177964T3 (es) * | 1996-03-30 | 2002-12-16 | Science Park Raf S P A | Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores. |
| US7011812B1 (en) | 1996-05-03 | 2006-03-14 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
| IT1289728B1 (it) | 1996-12-10 | 1998-10-16 | Sorin Biomedica Cardio Spa | Dispositivo di impianto e corredo che lo comprende |
| US7144991B2 (en) | 1999-06-07 | 2006-12-05 | Aletheon Pharmaceuticals, Inc. | Streptavidin expressed gene fusions and methods of use thereof |
| IT1317835B1 (it) | 2000-02-15 | 2003-07-15 | San Raffaele Centro Fond | Citochine modificate per uso nella terapia del cancro. |
| US7109303B2 (en) | 2000-02-15 | 2006-09-19 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
| US7309694B2 (en) | 2000-02-15 | 2007-12-18 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
| WO2001097855A2 (en) | 2000-06-20 | 2001-12-27 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
| ITRM20010079A1 (it) | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
| GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| ITRM20030196A1 (it) | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
| JP5631733B2 (ja) | 2007-04-04 | 2014-11-26 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ | 抗ＥｐＣＡＭ抗体およびその使用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07110815B2 (ja) * | 1985-11-18 | 1995-11-29 | ボ−ド・オブ・リ−ジェンツ、ザ・ユニバ−シティ−・オブ・テキサス・システム | 画像及びスペクトル向上（およびスペクトルシフト）のためのポリキレ−ト剤 |
| US4863713A (en) * | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
-
1990
- 1990-12-21 IT IT06805390A patent/IT1245748B/it active IP Right Grant
-
1991
- 1991-12-13 EP EP91121419A patent/EP0496074B1/en not_active Expired - Lifetime
- 1991-12-13 DE DE69123235T patent/DE69123235T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69123235D1 (de) | 1997-01-02 |
| IT1245748B (it) | 1994-10-14 |
| DE69123235T2 (de) | 1997-06-05 |
| EP0496074A1 (en) | 1992-07-29 |
| IT9068053A1 (it) | 1992-06-22 |
| EP0496074B1 (en) | 1996-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IT9068053A0 (it) | Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi e terapia di affezioni tumorali e suo impiego | |
| IL93840A0 (en) | Novel monoclonal antibody to novel antigen associated with human tumors | |
| KR880700061A (ko) | 인체 암종양과 관련된 항원에 대한 단클론성 항체 | |
| HUP0200537A2 (en) | Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases | |
| IT8319234A0 (it) | Procedimento per la produzione di anticorpi monoclonali umani. | |
| EP0161941A3 (en) | Monoclonal antibody useful in the diagnosis of human stomach or breast cancer | |
| DE3783277D1 (de) | Monoklonaler antikoerper gegen humanes lungenkarzinom. | |
| NO975621D0 (no) | Höyaffinitets-humane monoklonale antistoff spesifikke for RSV F-protein | |
| DE69319662D1 (de) | Monoklonale Antikörper gegen GP130-Protein | |
| IT1234215B (it) | Forma di dosaggio per il trattamento di malattie cardiovascolari | |
| PL354508A1 (en) | Antibody to human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin | |
| DE3854502D1 (de) | Gegen hiv-antigene spezifischer monoklonaler antikörper. | |
| IT1207589B (it) | Composizione di anticorpi monoclonali umani cross-protettivi. | |
| ITGE930053A1 (it) | Dispositivo per la fabbricazione di ovatte. | |
| FR2631239B1 (fr) | Anticorps monoclonal humain et hybridome le produisant | |
| IT1243924B (it) | Procedimento per la preparazione di dieteri | |
| KR890700358A (ko) | 인체 종양관련 항원 | |
| EP0460607A3 (en) | Novel monoclonal antibody to novel antigen associated with human tumors | |
| NO174110C (no) | Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet | |
| DK717888A (da) | Monoklonale antistoffer | |
| IT1239065B (it) | Anticorpo monoclonale che inibisce l'azione biologica del fattore piastrinico 4 | |
| DE3787239D1 (de) | Komplementabhängiger zytolytischer monoklonaler Antikörper gegen Trichomonas vaginalis und seine therapeutische und diagnostische Verwendung. | |
| DE69129582D1 (de) | Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay | |
| IT8819526A0 (it) | Intermedi e procedimenti per lapreparazione di composti tetrazolici antipercolestorolemici. | |
| IL86960A0 (en) | Preparation of human monoclonal antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 0001 | Granted | ||
| TA | Fee payment date (situation as of event date), data collected since 19931001 |
Effective date: 19981231 |